Article
New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells.
All News
Article
Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many confounding parameters, such as disease duration, disease state, and disease activity come into play. A promising session explored comorbidities in Rheumatoid Arthritis, in particular cancer and cardiovascular events. Here are my takeaways.
Article
Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.
Janet Pope
Tweet
Should we screen for #lung #cancer in #SSc high risk Pts? When >10 yrs?
Greek cohort of SSc since 1995
Disease duration 12 yrs,
smoking lung ca group ⬆️58% vs 29%
⬆️dcSSc
⬆️immunosuppression
OR >4X lung ca if dcSSc, IS
Less #DU
#PO0940 @RheumNow @eular_org #EULAR2025 https://t.co/L2zEkP8pAc
Mrinalini Dey
Tweet
In CareRA pooled analysis, 1 in 3 early RA pts had persistent impact (pain, fatigue, HAQ) despite improved inflammation. Female sex, longer symptom duration & low CRP were predictive. Pts more often escalated to b/tsDMARDs → risk of overtreatment?
@RheumNow #EULAR2025 #OP0330
David Liew
Tweet
We can control inflammation in RA, but some pts still struggle with disease impact, despite improving with bDMARDs:
- lower inflamm
- higher comorbidities
Doesn’t necessarily map to fibromyalgia dx
Beyond Rx, this is the critical question
CareRA/2000
#EULAR2025 OP0330 @RheumNow https://t.co/Th3smMgtVb
Jiha Lee
Tweet
Tofacitinib vs biologics in PsA:
📍MI/stroke ✅ similar
📍Serious infection ✅ similar
📍Malignancy ✅ similar
📍VTE ❌ higher vs TNFi (aHR 0.26)
Large US claims study (n=48k)
Abstract POS0296 @RheumNow #EULAR2025
Adela Castro
Tweet
High dose NSAIDs and incidence of HTN in axSpA?
In pts with early axSpA(age at baseline 33.2 years) data from DESIR cohort showed that after adjusting for confounders,high dose NSAID use was not associated with incident hypertension (HR 1.01, 95% CI 0.98-1.02).
Interesting to
David Liew
Tweet
Rheumatoid nodules are fascinating. If methotrexate nodulosis is a factor, why has their rate gone down when MTX use has gone up?
Environmental factors? Something else? It’s still a bit of a mystery - we still don’t know why
Christopher Edwards #EULAR2025 @RheumNow https://t.co/8LJYNRybve
David Liew
Tweet
Maybe the pathogenesis gives us a clue on how to target things?
Possibly the treatments which take down synovitis might not always help with nodules
Christopher Edwards #EULAR2025 @RheumNow https://t.co/T6QHCS8709
Md Yuzaiful Md Yusof
Tweet
#EULAR2025 Abstr#POS0320 Data from TULIP+LTE compared to Lupus Toronto Cohort as Control showed Anifrolumab reduced organ damage progression up to 4 years vs real-world SOC in #SLE. Effect continued to 10yrs using novel extrapolate analysis @RheumNow https://t.co/bkjZCZ8xGr
Md Yuzaiful Md Yusof
Tweet
#EULAR2025 Abstr#POS0321 In addition to complete renal response attainment as you already know, exploratory analysis from REGENCY showed Obinutuzumab+SOC reduced #lupus nephritis flare and unfavourable kidney outcomes vs PBO+SOC. Longterm kidney survival protection @RheumNow https://t.co/vRFb94TXaQ
David Liew
Tweet
How to treat rheumatoid vasculitis
#EULAR2025 @AshimaMakol @RheumNow https://t.co/A8oqPd6bJx
David Liew
Tweet
Should we still be worried about lymphoma developing in RA patients?
Incidence has plummeted with modern therapy, although still a small risk. TNFi and other bDMARDs don’t seem to confer any real risk.
So what should our approach be?
Karin Hellgren #EULAR2025 @RheumNow https://t.co/9ZodpojSaz
Md Yuzaiful Md Yusof
Tweet
#EULAR2025 Abstr#POS0991 RCT showed Adjuvanted Herpes Zoster vaccination appeared safe in #SLE upto 1 year. However, humoral and cellular responses declined over time. Longer follow up needed to ascertain frequency of vaccine to be repeated @RheumNow https://t.co/FcUi1OfBLu
David Liew
Tweet
What kills in GCA?
Greek national prospective cohort, small numbers and no doubt some channeling bias, but:
Steroids (absence of DMARD use) is more of a factor than CV disease in GCA mortality.
With new options, all GCA pts should be on something
#EULAR2025 POS0960 @RheumNow https://t.co/Wmvf6tEvaF
Janet Pope
Tweet
#digital #ulcers in #scleroderma🎯
Retrospective #iloprost vs #selexipag
👇
BIG advantage of oral #prostacyclin receptor #agonist vs iloprost
healing faster
⬇️ulcers
Selexipag used in iloprost failures; ⬇️IV access
WOW! RCT needed #OP035
#EULAR2025 @RheumNow @eular_org https://t.co/6y9LwIlQkd
Dr. John Cush
Tweet
SLE Preview: advances to achieve deep B-cell depletion
The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus (SLE). Its main principle is to induce deep B-cell depletion, with the hope to reset https://t.co/OzQ05YFZfb
Jiha Lee
Tweet
🎯 Early MTX hits the mark — but only in ACPA-negative.
In TREAT EARLIER, 1 year of MTX led to lasting benefits at 5 years:
➖ Less RA
➖ Better function
❌ No benefit in ACPA+
Abstract#OP0324 @RheumNow #EULAR2025
Janet Pope
Tweet
#ANCA #vasculitis is not created equally
REVEAL cohort 588 ANCA
Initial & 12 months #BVAS (activity index)
mean ⬇️BVAS over 1 yr in all groups
#GPA #MPA #eGPA
5yr survival not = over time
⬆️survival in eGPA & GPA vs MPA
#POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS
